EU and US could reach trade deal this weekend - Reuters
On Monday, BMO Capital Markets sustained its Market Perform rating and $61.00 price target on Bristol-Myers Squibb Co. (NYSE:BMY) shares, a prominent player in the pharmaceuticals industry with a market capitalization of $121.8 billion. According to InvestingPro data, the company maintains strong fundamentals with a 75% gross profit margin and has consistently paid dividends for 55 consecutive years. The firm’s analyst, Evan David Seigerman, provided insights into the company’s recent performance, particularly focusing on the schizophrenia drug Cobenfy. According to the latest data tracked through IQVIA, Cobenfy’s total prescriptions (TRx) witnessed a 7.4% week-over-week increase, setting a new record with 1,443 prescriptions.
Seigerman projects that Cobenfy will achieve approximately 13,980 prescriptions in the first quarter of 2025, which could result in revenue of around $28 million. This figure represents a 42% rise compared to the current consensus. The analyst’s forecast is bolstered by the observed weekly TRx trends, which have instilled greater confidence in these estimates.
Furthermore, BMO Capital has adjusted its expectations for gross to net rebates for Cobenfy to 28% for the first quarter of 2025. This adjustment aligns the rebates more closely with the statutory minimums required for Medicaid. Despite this increase in rebates, the firm’s model currently anticipates that Cobenfy will generate $22 million in revenue for the first quarter of the year.
The continued tracking of Cobenfy’s performance through IQVIA will be crucial for BMO Capital in assessing the drug’s market traction and financial impact on Bristol-Myers Squibb. The analyst’s comments reflect a cautious optimism based on the drug’s prescription trends, which are exceeding initial expectations and could signal a positive trajectory for Bristol-Myers Squibb’s latest product offering. InvestingPro analysis suggests the company is slightly undervalued, with analysts projecting profitability this year and strong free cash flow yield. For deeper insights into BMY’s valuation and growth prospects, including access to comprehensive Pro Research Reports covering 1,400+ top stocks, consider exploring InvestingPro.
In other recent news, Bristol Myers Squibb has announced several significant developments. The European Commission has granted expanded approval for Bristol Myers Squibb’s CAR-T cell therapy, Breyanzi, to treat adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This approval follows the Phase 2 TRANSCEND FL study, which showed a high overall response rate of 97.1% and a complete response rate of 94.2% among patients. Meanwhile, the Committee for Medicinal Products for Human Use has endorsed a subcutaneous formulation of Bristol Myers Squibb’s cancer drug, Opdivo, for multiple approved adult solid tumors. Additionally, the company has entered into a definitive agreement to acquire 2seventy bio for approximately $286 million, with the transaction expected to close in the second quarter of 2025. This acquisition aims to enhance Bristol Myers Squibb’s portfolio, particularly focusing on maximizing the value of Abecma, a therapy for multiple myeloma. On the analyst front, UBS has maintained a Neutral rating on Bristol Myers Squibb with a price target of $60, focusing on the performance of Cobenfy. UBS analysts project that Cobenfy could achieve significant sales growth by 2025, despite recent stagnation in prescriptions. These developments highlight Bristol Myers Squibb’s continued efforts in expanding its treatment options and strategic acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.